191673-60-6

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 82511-02-2 ((3-bromobut-3-en-1-yl)oxy)(tert-butyl)dimethylsilane 
• 191673-76-4 methyl 3-(3,4-dichlorophenyl)-3-butenoate 
• 1034183-25-9 3-(3,4-Dichloro-phenyl)-but-3-enoic acid 
• 272775-65-2 3-(3',4'-dichlorophenyl)-3-buten-1-ol 
• 18282-59-2 4-bromo-1,2-dichlorobenzene 
• 191673-32-2 (R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3,4-dichloro-phenyl)-butane-1,2-diol 
• 191673-30-0 tert-Butyl-[3-(3,4-dichloro-phenyl)-but-3-enyloxy]-dimethyl-silane 
• 191673-50-4 [(R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3,4-dichloro-phenyl)-2-hydroxy-butyl]-(2-hydroxy-ethyl)-carbamic acid tert-butyl ester 

Downstream Products

• 191673-56-0 (R)-2-(2-(3,4-dichlorophenyl)morpholin-2-yl)ethanol 
• 191673-57-1 (2R)-2-[2-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethanol 

Relevant academic research and scientific papers

Combined tachykinin receptor antagonist: Synthesis and stereochemical structure-activity relationships of novel morpholine analogues

We report herein the synthesis and stereochemical structure-activity relationships of novel morpholine analogues 12 and 13 with regards to NK1, NK2 and NK3 tachykinin receptor binding affinity. An essential requirement for more potent binding affinities was controlled by absolute configuration. (S,R)-12 and (S,R)-13 exhibited high binding affinities for NK1, NK2 and NK3 receptors. (C) 2000 Elsevier Science Ltd. All rights reserved.

Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use

Compounds of the formula and quaternary ammonium ions thereof, wherein R1 and R2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C1-C4 alkylene or C2-C4, alkenylene; D is oxygen; E is C2 alkylene; G is C1-C4 alkylene or C2-C4 alkenylene; and L is -C(R4)(R5), wherein R4 and R5 together with the carbon atom to which they are attached represent a C5-C10 cycloalkyl or a C5-C10 heterocyclic. Especially preferred are compounds wherein L represents wherein J is a C1-C6 alkylene; Ar is a ring carbocyclic or aromatic heterocyclic and S*->O is a sulfoxide in which the sulfur atom is in the 5-configuration. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK1 and NK2 receptors.

An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin- 2-yl]ethanols, key intermediates of tachykinin receptor antagonist

We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2[(2R)-arylmorpholin-2-yl]ethanols 1a- d, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asymmetric dihydroxylation of 4a-d was employed to introduce the required absolute stereochemistry, and cyclization of 7a-d was accomplished by the Mitsunobu reaction.